GSK disclose discontinued operations from Q2 2022
Issued: 5 July 2022, London UK
GSK to disclose discontinued operations from Q2 2022
GSK plc (LSE/NYSE: GSK) will as a consequence of its proposed demerger of the Consumer Healthcare business on 18 July 2022 disclose its Q2 2022 results on 27 July 2022 in accordance with the requirements of IFRS 5 - 'Non-current Assets Held for Sale and Discontinued Operations'. GSK has now satisfied the formal criteria for treating Consumer Healthcare as a 'Discontinued operation' effective from 30 June 2022, accordingly it will no longer present the Consumer Healthcare business within 'Continuing operations' and will also disclose the assets and liabilities of the Consumer Healthcare business as assets and liabilities held for sale/distribution. The GSK Group ('Group') will continue to consolidate the business for reporting purposes until the demerger of the Consumer Healthcare business has completed. Details of the demerger are included in the published Prospectus and Circular for the proposed demerger of the Consumer Healthcare business to form Haleon plc ('Haleon').
Requirements of IFRS 5 - 'Non-current Assets Held for Sale and Discontinued Operations'
GSK has satisfied the requirements under IFRS 5 to treat the Consumer Healthcare business as a 'disposal group' effective from 30 June 2022, as it is expected that the carrying amount of the disposal group will be recovered principally through disposal and a distribution, it is available for distribution in its present condition (subject only to the steps to be completed that are usual and customary for the demerger of a business) and it is considered highly probable (the expected date of the demerger being 18 July 2022).
As a consequence of meeting these formal criteria, the Consumer Healthcare business will no longer be presented as 'Continuing operations', which will result in the following changes to the presentation of the Q2 2022 results on 27 July 2022:
· Turnover, cost of sales, SG&A expenses, research and development expenses, royalty income, other income and expenses, operating profit, profit before taxation, profit after taxation from continuing operations and Adjusted[1] results of the Group will be presented on the basis of the 'Continuing operations' of the Group, with the component of the post-tax Group results attributable to 'Discontinued operations' presented as a single line item in the Income Statement. The Total post-tax results of the Group will include 'Continuing' and 'Discontinued operations'.
· The earnings per share of the Group will be presented separately between the earnings per share attributable to 'Continuing operations' and earnings per share attributable to 'Discontinued operations'. Adjusted earnings per share will only be presented for 'Continuing operations'. Earnings per share for Q2 2022 and for prior periods will be adjusted to reflect the impact of the GSK share consolidation expected to take place following the demerger but prior to the Q2 results announcement on 27 July 2022. The earnings per share figures presented below are based on the current pre-consolidation GSK share capital structure.
· Comparative income statement information will be re-presented on a consistent basis;
· GSK will no longer present a Consumer Healthcare segment and those items previously reported within the Consumer Healthcare segment that do not form part of the 'Discontinued operations' of the Group will be shown as part of 'Continuing operations' and reported within either the Commercial Operations segment or Corporate and unallocated costs, as appropriate;
· Disclosure of the Total turnover, expenses, pre-tax profit and tax expense of the 'Discontinued operations' will be reported as an additional disclosure on a Total basis only;
· The respective totals of the net cash inflow from operations, the net cash inflow from operating activities, the net cash flow from investing activities and the net cash flow from financing activities will be shown split between 'Continuing operations' and 'Discontinued operations'. Free cash flow[2] will be presented only for 'Continuing operations';
· The assets and liabilities of the Consumer Healthcare 'disposal group' will be presented on the face of the Group balance sheet as assets held for sale/distribution and liabilities held for sale/ distribution respectively as current assets and liabilities. Analysis of the main categories of assets and liabilities reported as assets and liabilities held for sale/distribution will be presented as a note to the financial statements.
Impact of the application of the requirements of IFRS 5
The application of the requirements of IFRS 5 has no impact on the total post-tax results of the Group in the presentation of the restated historical information . However, as a result of the reclassification of the assets and liabilities of the Consumer Healthcare business (the 'disposal group') to assets and liabilities held for sale/ distribution with effect from 30 June 2022, they are held at the lower of carrying amount and fair value less costs to distribute and from that point onwards, depreciation and amortisation ceases on those tangible and intangible assets reclassified as part of the assets held for sale/distribution.
The application of IFRS 5 also has no impact on the total reported cash flows of the Group, although under the requirements of IFRS 5, the total for each category of the reported cash flows of the Group (net cash inflow from operations, cash flow from operating activities, cash flow from investing activities and cash flow from financing activities) should be presented split between 'Continuing' and 'Discontinued operations'.
As a result of the presentational changes, cash generated from operations for the full year 2021 was £7,249 million for 'Continuing operations' (Q1 2021: £406 million; Q1 2022: £2,353 million) and cash generated from operations was £1,994 million for 'Discontinued operations' (Q1 2021: £80 million; Q1 2022: £402 million).
Net cash inflow from continuing operating activities for the full year 2021 was £6,277 million (Q1 2021: £316 million; Q1 2022: £2,207 million) and n et operating cash flows attributable to discontinued activities was £1,675 million (Q1 2021: £15 million; Q1 2022: £335 million).
Net increase/(decrease) in cash and bank overdrafts from 'Continuing operations' for the full year 2021 was £(2,505) million (Q1 2021: £(900) million; Q1 2022: £283 million) and net increase/(decrease) in cash and bank overdrafts attributable to 'Discontinued operations' was £1,091 million (Q1 2021: £(193) million; Q1 2022: £6,639 million).
Impact on the Group's reportable segments
The Group presents its segmental results based on the Adjusted results of the Group from 'Continuing operations' and will therefore exclude the Consumer Healthcare business from Q2 2022. As a result, the Group will no longer report a Consumer Healthcare segment. The Group will continue to report the results of the Commercial Operations segment and the Research and Development segment.
As a result of reporting the results of the continuing operations of GSK and no longer reporting the Consumer Healthcare segment, the results of the Commercial Operations segment and those costs shown under Corporate and unallocated costs for prior periods have been revised. This reflects the following principal changes:
· Certain revenues and costs reported within the Consumer Healthcare segment will be split between the 'Continuing operations' and 'Discontinued operations' of the Group income statement, primarily reflecting contract manufacturing that will continue to be performed by GSK on behalf of the Haleon group after the demerger. The value of the sales and related costs that will be included in the 'Continuing operations' of the Group will be reported as part of the Commercial Operations segment;
· The Consumer Healthcare segment included some markets that were not within the perimeter of the Consumer Healthcare joint venture with Pfizer and will not be part of the Consumer Healthcare business to be demerged. These will be reported as part of the Commercial Operations segment.
· Corporate costs that were allocated to the Consumer Healthcare segment and will continue to be incurred by GSK after the demerger. These costs will be reported within the Corporate and unallocated costs as 'Continuing operations'. Corporate costs incurred by GSK in prior periods on behalf of Consumer Healthcare that have been transferred to Haleon group companies ahead of the demerger will be reported as part of 'Discontinued operations'.
The impact of these 'Continuing operations' sales and costs previously reported in the Consumer Healthcare segment and that do not form part of the 'Discontinued operations' do not materially change the reported performance of the Commercial Operations segment.
The tables below set out the revised format for reporting the income statement under the requirements of IFRS 5 that will be applied from the Q2 2022 results, as applied to the Q1 2021, Q2 2021, Q3 2021, Q4 2021 and full year 2021 and the Q1 2022 results.
An Microsoft Excel version of this data is available on www.gsk.com .
About GSK
GSK is a science-led global healthcare company. For further information please visit www.gsk.com/about-us .
|
GSK enquiries: |
|
|
|
|
Media enquiries: |
Tim Foley |
+44 (0) 20 8047 5502 |
(London) |
|
|
Simon Moore |
+44 (0) 20 8047 5502 |
(London) |
|
|
Madeleine Breckon |
+44 (0) 20 8047 5502 |
(London) |
|
|
Kathleen Quinn |
+1 202 603 5003 |
(Washington DC) |
|
|
Lyndsay Meyer |
+1 202 302 4595 |
(Washington DC) |
|
|
|
|
|
|
Analyst/Investor enquiries: |
Nick Stone |
+44 (0) 7717 618834 |
(London) |
|
|
Sonya Ghobrial |
+44 (0) 7392 784784 |
(Consumer) |
|
|
James Dodwell |
+44 (0) 20 8047 2406 |
(London) |
|
|
Mick Readey |
+44 (0) 7990 339653 |
(London) |
|
|
Josh Williams |
+44 (0) 7385 415719 |
(London) |
|
|
Jeff McLaughlin |
+1 215 751 7002 |
(Philadelphia) |
Cautionary statement regarding forward-looking statements
GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described in the Company's Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
This Announcement does not constitute statutory accounts of the Group within the meaning of sections 434(3) and 435(3) of the Companies Act 2006. The information for 2021 and 2020 has been derived from the full Group accounts published in the Annual Report 2021.
Results by quarter for 2021, full year 2021 and Q1 2022 results presented under IFRS 5
|
|
|
|
Total Results |
|
|
|
Q1 2021 £m |
|
Q2 2021 £m |
|
Q3 2021 £m |
|
Q4 2021 £m |
|
Full Year £m |
|
Q1 2022 £m |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing Operations |
|
|
|
|
|
|
|
|
|
|
|
|
Turnover |
5,155 |
|
5,838 |
|
6,627 |
|
7,076 |
|
24,696 |
|
7,190 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
(1,654) |
|
(1,708) |
|
(2,016) |
|
(2,785) |
|
(8,163) |
|
(2,717) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit |
3,501 |
|
4,130 |
|
4,611 |
|
4,291 |
|
16,533 |
|
4,473 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration |
(1,509) |
|
(1,689) |
|
(1,679) |
|
(2,193) |
|
(7,070) |
|
(1,812) |
|
Research and development |
(1,060) |
|
(1,167) |
|
(1,416) |
|
(1,376) |
|
(5,019) |
|
(1,103) |
|
Royalty income |
88 |
|
77 |
|
115 |
|
137 |
|
417 |
|
138 |
|
Other operating income / (expense) |
190 |
|
(76) |
|
(251) |
|
(368) |
|
(505) |
|
592 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit |
1,210 |
|
1,275 |
|
1,380 |
|
491 |
|
4,356 |
|
2,288 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Finance income |
6 |
|
4 |
|
3 |
|
1 |
|
14 |
|
8 |
|
Finance costs |
(198) |
|
(189) |
|
(195) |
|
(187) |
|
(769) |
|
(205) |
|
Loss on disposal of interests in associates |
- |
|
(36) |
|
- |
|
- |
|
(36) |
|
- |
|
Share of after tax profits of associates and joint ventures |
16 |
|
16 |
|
3 |
|
(2) |
|
33 |
|
(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit before taxation |
1,034 |
|
1,070 |
|
1,191 |
|
303 |
|
3,598 |
|
2,090 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation |
(155) |
|
201 |
|
(246) |
|
117 |
|
(83) |
|
(327) |
|
Tax rate % |
15.0% |
|
(18.8%) |
|
20.7% |
|
(38.6%) |
|
2.3% |
|
15.6% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after tax from continuing operations |
879 |
|
1,271 |
|
945 |
|
420 |
|
3,515 |
|
1,763 |
|
Profit after tax from discontinued operations |
381 |
|
267 |
|
423 |
|
510 |
|
1,581 |
|
404 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit after tax for the period |
1,260 |
|
1,538 |
|
1,368 |
|
930 |
|
5,096 |
|
2,167 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Profit (Loss) attributable to non-controlling interests from continuing operations |
80 |
|
57 |
|
69 |
|
(6) |
|
200 |
|
275 |
|
Profit attributable to shareholders from continuing operations |
799 |
|
1,214 |
|
876 |
|
4 26 |
|
3,315 |
|
1,488 |
|
Profit attributable to non-controlling interests from discontinued operations |
107 |
|
86 |
|
131 |
|
187 |
|
511 |
|
90 |
|
Profit attributable to shareholders from discontinued operations |
274 |
|
181 |
|
292 |
|
323 |
|
1,070 |
|
314 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total profit attributable to non-controlling interests |
187 |
|
143 |
|
200 |
|
181 |
|
711 |
|
365 |
|
Total profit attributable to shareholders |
1,073 |
|
1,395 |
|
1,168 |
|
749 |
|
4,385 |
|
1,802 |
|
|
1,260 |
|
1,538 |
|
1,368 |
|
930 |
|
5,096 |
|
2,167 |
|
Earnings per share from continuing operations |
16.0p |
|
24.3p |
|
17.6p |
|
8.4p |
|
66.3p |
|
29.7p |
|
Earnings per share from discontinued operations |
5.5p |
|
3.6p |
|
5.7p |
|
6.6p |
|
21.3p |
|
6.2p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total earnings per share[3] |
21.5p |
|
27.9p |
|
23.3p |
|
15.0p |
|
87.6p |
|
35.9p |
|
Reconciliation of Total Results from Continuing operations to Adjusted Results from Continuing operations
|
||||||||||||
|
|
Q1 2021 £m |
|
Q2 2021 £m |
|
Q3 2021 £m |
|
Q4 2021 £m |
|
Full Year £m |
|
Q1 2022 £m |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Operating profit from continuing operations |
1,210 |
|
1,275 |
|
1,380 |
|
491 |
|
4,356 |
|
2,288 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible amortisation |
191 |
|
186 |
|
190 |
|
194 |
|
761 |
|
186 |
|
|
Intangible impairment |
13 |
|
7 |
|
264 |
|
62 |
|
346 |
|
(16) |
|
|
Major restructuring |
66 |
|
102 |
|
97 |
|
159 |
|
424 |
|
51 |
|
|
Transaction related |
116 |
|
130 |
|
290 |
|
604 |
|
1,140 |
|
347 |
|
|
Divestments, significant legal and other items |
(271) |
|
(59) |
|
(12) |
|
(193) |
|
(535) |
|
(912) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operating profit from continuing operations |
1,325 |
|
1,641 |
|
2,209 |
|
1,317 |
|
6,492 |
|
1,944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Earnings per share from continuing operations3 |
16.0p |
|
24.3p |
|
17.6p |
|
8.4p |
|
66.3p |
|
29.7p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Intangible amortisation |
3.1p |
|
3.0p |
|
3.1p |
|
3.0p |
|
12.2p |
|
3.0p |
|
|
Intangible impairment |
0.2p |
|
0.1p |
|
4.0p |
|
1.0p |
|
5.3p |
|
(0.2)p |
|
|
Major restructuring |
1.1p |
|
1.6p |
|
1.5p |
|
2.7p |
|
6.9p |
|
0.8p |
|
|
Transaction related |
1.1p |
|
1.1p |
|
4.0p |
|
8.2p |
|
14.4p |
|
8.1p |
|
|
Divestments, significant legal and other items |
(4.5)p |
|
(7.5)p |
|
(0.3)p |
|
(4.5)p |
|
(16.8)p |
|
(15.5)p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Earnings per share from continuing operations3 |
16.9p |
|
22.6p |
|
29.9p |
|
18.8p |
|
88.3p |
|
25.8p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted result from continuing operations
Adjusted results are from continuing operations and exclude the Consumer Healthcare business.
|
||||||||||||
|
|
Q1 2021 £m |
|
Q2 2021 £m |
|
Q3 2021 £m |
|
Q4 2021 £m |
|
Full Year £m |
|
Q1 2022 £m |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover |
5,155 |
|
5,838 |
|
6,627 |
|
7,076 |
|
24,696 |
|
7,190 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales |
(1,435) |
|
(1,522) |
|
(1,797) |
|
(2,592) |
|
(7,346) |
|
(2,527) |
|
|
Selling, general and administration |
(1,462) |
|
(1,646) |
|
(1,623) |
|
(2,018) |
|
(6,749) |
|
(1,769) |
|
|
Research and development |
(1,021) |
|
(1,107) |
|
(1,112) |
|
(1,285) |
|
(4,525) |
|
(1,088) |
|
|
Royalty income |
88 |
|
78 |
|
114 |
|
136 |
|
416 |
|
138 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Operating profit |
1,325 |
|
1,641 |
|
2,209 |
|
1,317 |
|
6,492 |
|
1,944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net finance cost |
(190) |
|
(185) |
|
(190) |
|
(186) |
|
(751) |
|
(197) |
|
|
Share of after tax profits of associates and joint ventures |
16 |
|
16 |
|
3 |
|
(2) |
|
33 |
|
(1) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted profit before taxation |
1,151 |
|
1,472 |
|
2,022 |
|
1,129 |
|
5,774 |
|
1,746 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Taxation |
(195) |
|
(244) |
|
(402) |
|
(77) |
|
(918) |
|
(291) |
|
|
Tax rate % |
16.9% |
|
16.6% |
|
19.9% |
|
6.8% |
|
15.9% |
|
16.7% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted profit after taxation |
956 |
|
1,228 |
|
1,620 |
|
1,052 |
|
4,856 |
|
1,455 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted profit attributable to non-controlling interests |
112 |
|
99 |
|
121 |
|
109 |
|
441 |
|
161 |
|
|
Adjusted profit attributable to shareholders |
844 |
|
1,129 |
|
1,499 |
|
943 |
|
4,415 |
|
1,294 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted earnings per share3 |
16.9p |
|
22.6p |
|
29.9p |
|
18.8p |
|
88.2p |
|
25.8p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of Covid solutions[4] |
(0.2)p |
|
3.8p |
|
1.5p |
|
3.8p |
|
8.8p |
|
3.2p |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating profit by segment (continuing operations)
|
Operating profits by segment are from continuing operations and exclude the Consumer Healthcare business.
|
||||||||||||
|
|
Q1 2021 £m |
|
Q2 2021 £m |
|
Q3 2021 £m |
|
Q4 2021 £m |
|
Full Year £m |
|
Q1 2022 £m |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial Operations |
2,446 |
|
2,872 |
|
3,461 |
|
2,703 |
|
11,482 |
|
3,120 |
|
|
Research and Development |
(1,030) |
|
(1,118) |
|
(1,139) |
|
(1,281) |
|
(4,568) |
|
(1,095) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Segment profit |
1,416 |
|
1,754 |
|
2,322 |
|
1,422 |
|
6,914 |
|
2,025 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Corporate & other unallocated costs |
(91) |
|
(113) |
|
(113) |
|
(105) |
|
(422) |
|
(81) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted operating profit |
1,325 |
|
1,641 |
|
2,209 |
|
1,317 |
|
6,492 |
|
1,944 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Impact of Covid solutions |
(12) |
|
233 |
|
97 |
|
214 |
|
532 |
|
194 |
|
Commercial operations turnover
|
|
|||||||||||||||||||||
|
|
Q1 2021 £m |
|
Q2 2021 £m |
|
Q3 2021 £m |
|
Q4 2021 £m |
|
Full Year £m |
|
Q1 2022 £m |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Specialty |
1,575 |
|
1,879 |
|
2,019 |
|
2,778 |
|
8,251 |
|
3,135 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Vaccines |
1,224 |
|
1,571 |
|
2,174 |
|
1,809 |
|
6,778 |
|
1,669 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Respiratory |
1,492 |
|
1,514 |
|
1,492 |
|
1,550 |
|
6,048 |
|
1,535 |
|
|||||||||
|
Other General Medicines |
864 |
|
874 |
|
942 |
|
939 |
|
3,619 |
|
851 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
General Medicines |
2,356 |
|
2,388 |
|
2,434 |
|
2,489 |
|
9,667 |
|
2,386 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Total Commercial Operations |
5,155 |
|
5,838 |
|
6,627 |
|
7,076 |
|
24,696 |
|
7,190 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
US |
2,218 |
|
2,782 |
|
3,390 |
|
3,524 |
|
11,914 |
|
3,586 |
|
|||||||||
|
Europe |
1,257 |
|
1,260 |
|
1,333 |
|
1,520 |
|
5,370 |
|
1,660 |
|
|||||||||
|
International |
1,680 |
|
1,796 |
|
1,904 |
|
2,032 |
|
7,412 |
|
1,944 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Total Commercial Operations |
5,155 |
|
5,838 |
|
6,627 |
|
7,076 |
|
24,696 |
|
7,190 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||
|
Impact of Covid solutions |
- |
|
276 |
|
209 |
|
920 |
|
1,405 |
|
1,307 |
|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
[1] Total and Adjusted Results - Adjusted results are a non-IFRS measure that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Adjusted results exclude the profits from discontinued operations from the Consumer Healthcare business and the items defined on page 20 of the Q1 2022 results announcement in relation to our continuing operations. The Q1 2022 results announcement is available at www.gsk.com
[2] Free cash flow - Free cash flow is a non-IFRS measure that may be considered in addition to, but not as a substitute for, or superior to, information presented in accordance with IFRS. Free cash flow is defined on page 42 of the Q1 2022 results announcement. The Q1 2022 results announcement is available at www.gsk.com
[3] Earnings per share for Q2 2022 and for prior periods will be adjusted to reflect the impact of the GSK share consolidation expected to take place following the demerger (the earnings per share figures presented are based on the current pre-consolidation GSK share capital structure).
[4] COVID-19 solutions include the sales of pandemic adjuvant and other COVID-19 solutions including vaccine manufacturing and Xevudy and the associated costs but does not include reinvestment in R&D. This categorisation is used by management and we believe is helpful to investors through providing clarity on the results of the Group by showing the contribution to growth from COVID-19 solutions.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 1 day ago Savannah Energy
- 1 day ago Buccaneer Energy PLC
- 1 day ago Savannah Energy
- 1 day ago Carclo
- 1 day ago Schroder Japan Growth Fund